Comparative Pharmacology
Head-to-head clinical analysis: PERIACTIN versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERIACTIN versus X TROZINE L A.
PERIACTIN vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine
Antihistamine